...
首页> 外文期刊>Journal of Ophthalmology >Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients
【24h】

Selective Retina Therapy with Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients

机译:实时反馈控制剂量法选择性视网膜疗法治疗韩国患者的急性特发性中枢性浆液性脉络膜视网膜病变

获取原文
           

摘要

Purpose. To evaluate short-term treatment outcomes following selective retina therapy (SRT) with real-time feedback-controlled dosimetry in Korean patients with acute idiopathic central serous chorioretinopathy (CSC). Methods. Sixteen eyes (16 patients) with acute idiopathic CSC (symptom duration??3 months) were included in this retrospective study. All patients underwent a single session of SRT with real-time feedback-controlled dosimetry. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) before and 3 months after treatment were examined and compared. Results. The logarithm of minimal angle of resolution BCVA was significantly better 3 months after treatment (0.16?±?0.18) than at the time of diagnosis (0.27?±?0.18, ). Additionally, subretinal fluid had resolved in all 16 eyes 3 months after treatment and CFT was significantly lower 3 months after treatment (215.6?±?17.9?μm) than at baseline (441.4?±?124.8?μm, ). No notable SRT-related complications were observed during the study period. Conclusion. The results of the present study suggest that SRT is a useful therapeutic option for patients with acute idiopathic CSC. Further studies are required to better understand the long-term efficacy of this treatment. This trial is registered with clinical trial registration number NCT03339856.
机译:目的。为了评估韩国特发性急性特发性中央浆液性脉络膜视网膜病变(CSC)患者接受选择性视网膜治疗(SRT)和实时反馈控制剂量测定后的短期治疗效果。方法。这项回顾性研究纳入了16眼(16例)急性特发性CSC(症状持续时间≤3个月)。所有患者均接受单次SRT治疗,并带有实时反馈控制剂量法。检查并比较治疗前和治疗后3个月的最佳矫正视力(BCVA)和中央凹中央厚度(CFT)。结果。治疗3个月(0.16±0.18)后,最小分辨角BCVA的对数明显优于诊断时(0.27±0.18)。此外,治疗后3个月,所有16只眼的视网膜下液均已消退,治疗后3个月(215.6±±17.9μm)的CFT显着低于基线(441.4±±124.8μm,)。在研究期间未观察到明显的SRT相关并发症。结论。本研究的结果表明,SRT是急性特发性CSC患者的一种有用的治疗选择。需要进一步研究以更好地了解这种治疗的长期疗效。该试验已通过临床试验注册号NCT03339856注册。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号